The ex-dividend date for Amgen (Nasdaq:AMGN) is tomorrow, May 14, 2013. Owners of shares as of market close today will be eligible for a dividend of 47 cents per share. At a price of $106.18 as of 9:30 a.m., the dividend yield is 1.8%.
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. NEW YORK ( TheStreet) -- The ex-dividend date for Amgen (Nasdaq: AMGN) is tomorrow, May 14, 2013. Owners of shares as of market close today will be eligible for a dividend of 47 cents per share. At a price of $106.18 as of 9:30 a.m. ET, the dividend yield is 1.8%. The average volume for Amgen has been 4.6 million shares per day over the past 30 days. Amgen has a market cap of $78.42 billion and is part of the health care sector and drugs industry. Shares are up 21.3% year to date as of the close of trading on Friday. Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. The company has a P/E ratio of 17.7, equal to the S&P 500 P/E ratio of 17.7.
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and notable return on equity. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. You can view the full Amgen Ratings Report. See our dividend calendar or top-yielding stocks list. Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100% See his top picks for 14-days FREE.